Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Lululemon updates bylaws to align with Delaware law, SEC universal proxy rules

Lululemon updates bylaws to align with Delaware law, SEC universal proxy rules

ReutersReuters2026/09/14 20:16
  • Lululemon adopted bylaw amendments effective Sept. 8, 2026, aligning governance provisions with recent Delaware law developments.
  • Changes tightened stockholder nomination and proposal procedures, reflecting SEC rules for universal proxy cards.
  • Revisions also updated meeting mechanics, including quorum standards and rules for adjournments and contested director elections.
  • New emergency bylaws were added to operate during disasters or other emergency conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lululemon Athletica Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001397187-26-000129), on September 14, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma